- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.12.25 | Avicena's LightBundle optical links operating at 4Gbps per lane with transmitter current as low as 100µA per LED | 1 | Semiconductor Today | ||
| AVICENA Aktie jetzt für 0€ handeln | |||||
| 17.11.25 | Avicena Advances microLED and Photo Detector Arrays to Enable the World's Lowest-Power AI Scale-up Optical Interconnects | 305 | Business Wire | Latest Avicena LightBundle technology delivers industry-leading Tx power of 80fJ/bit addressing next generation AI infrastructure requirements
Avicena, the leader in next-generation microLED interconnects... ► Artikel lesen | |
| 29.09.25 | Avicena Tech Corp.: Avicena Demonstrates Breakthrough Ultra-Low Power microLED Link at 200fJ/bit Tx Power | 301 | Business Wire | Avicena Is Showcasing an Ultra-low Power microLED Interconnect at 200fJ/bit of Transmitter Power Using Optimized Camera Sensor as the Receiver
Avicena, the leader in next-generation microLED interconnects... ► Artikel lesen | |
| 03.09.25 | Avicena Names Marco Chisari as New CEO | 460 | Business Wire | Amid unprecedented demand for ultra-low power optical interconnects in AI datacenters and future disaggregated memory fabrics, Avicena is poised for the next phase of growth
Avicena, the leader... ► Artikel lesen | |
| 14.05.25 | AvicenaTech, Corp.: Avicena Announces Series B Funding Round Led by Tiger Global with Participation from SK hynix | 1.042 | Business Wire | Amid unprecedented demand for ultra-low power optical interconnects in AI datacenters and future disaggregated memory fabrics, Avicena is preparing for the next phase of growth
Avicena, the leader... ► Artikel lesen | |
| 22.04.25 | Avicena Works with TSMC to Enable PD Arrays for LightBundle MicroLED-Based Interconnects | 553 | Business Wire | Avicena is working with TSMC to optimize silicon photodetector (PD) arrays for Avicena's LightBundle microLED-based interconnects aimed at AI scale-up networks with 1Tbps/mm I/O density and 1pJ/bit... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 79,02 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,89 | 0,00 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 51,08 | 0,00 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,970 | 0,00 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,435 | 0,00 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| EDGEWISE THERAPEUTICS | 30,250 | 0,00 % | Piper Sandler bekräftigt "Overweight"-Rating für Edgewise Therapeutics vor wichtigen Studiendaten | ||
| STRUCTURE THERAPEUTICS | 78,83 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,975 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 319,06 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TANGO THERAPEUTICS | 12,890 | 0,00 % | Expert Outlook: Tango Therapeutics Through The Eyes Of 4 Analysts | ||
| APOGEE THERAPEUTICS | 62,06 | 0,00 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| TREVI THERAPEUTICS | 11,100 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| IMMUNOVANT | 27,460 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,610 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| ARCELLX | 68,82 | 0,00 % | Stifel bestätigt Kaufempfehlung für Arcellx nach vielversprechenden Sicherheitsdaten |
Das Unternehmen AVICENA GROUP INC kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AVICENA GROUP INC finden Sie auf Wallstreet Online.